- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 239/95 - Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Patent holdings for IPC class C07D 239/95
Total number of patents in this class: 294
10-year publication summary
|
16
|
21
|
12
|
14
|
20
|
28
|
23
|
19
|
19
|
7
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 1879 |
19 |
| Araxes Pharma LLC | 91 |
13 |
| Bristol-myers Squibb Company | 5080 |
11 |
| Janssen Sciences Ireland Unlimited Company | 431 |
9 |
| Ideaya Biosciences, Inc. | 83 |
7 |
| Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. | 13 |
6 |
| Cerepeut, Inc. | 7 |
6 |
| Novartis AG | 11238 |
5 |
| The Regents of the University of California | 18943 |
5 |
| Amgen Inc. | 3779 |
5 |
| Chelsea Therapeutics, Inc. | 18 |
5 |
| Southern Research Institute | 207 |
5 |
| F. Hoffmann-La Roche AG | 7958 |
4 |
| Merck Patent GmbH | 5909 |
4 |
| Janssen Sciences Ireland UC | 256 |
4 |
| Rigel Pharmaceuticals, Inc. | 613 |
4 |
| University of Louisville Research Foundation, Inc. | 709 |
4 |
| Sumitomo Pharma Co., Ltd. | 626 |
4 |
| Hoffmann-La Roche Inc. | 3060 |
3 |
| AstraZeneca AB | 3042 |
3 |
| Other owners | 168 |